JPM2025: Regulation of artificial intelligence: Navigating a new frontier in health care

Full Article

Artificial intelligence (AI) is revolutionizing health care, impacting diagnostics, drug development, and clinical trials. As AI technologies advance, regulators globally are tasked with ensuring patient safety while promoting innovation. The article examines how existing regulations affect AI's role in health care, focusing on AI as a medical device, health data usage, and clinical trials.

The regulatory landscape varies significantly among key players like the FDA, MHRA, and EMA. Each agency is adapting its approach to address the unique challenges posed by AI, balancing safety and innovation. The article emphasizes the importance of collaboration between regulators and industry to navigate this evolving frontier.

• AI is transforming diagnostics, drug development, and clinical trials in health care.

• Regulators are adapting existing frameworks to address AI's unique challenges.

Key AI Terms Mentioned in this Article

Software as a Medical Device (SaMD)

SaMD refers to software intended for medical purposes, regulated similarly to medical devices.

Artificial Intelligence as a Medical Device (AIaMD)

AIaMD encompasses AI technologies used for diagnosing or treating medical conditions.

Regulatory Sandbox

A regulatory sandbox allows companies to test AI innovations in a controlled environment with regulatory oversight.

Companies Mentioned in this Article

U.S. Food and Drug Administration (FDA)

FDA is responsible for regulating AI technologies in health care, ensuring safety and effectiveness.

UK Medicines and Healthcare products Regulatory Agency (MHRA)

MHRA adopts a pro-innovation approach to regulate AI in medical devices, facilitating industry collaboration.

European Medicines Agency (EMA)

EMA focuses on ethical AI regulation, emphasizing patient safety and data protection in health care.

Get Email Alerts for AI News

By creating an email alert, you agree to AIleap's Terms of Service and Privacy Policy. You can pause or unsubscribe from email alerts at any time.

Latest Articles

Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive
TechCrunch 6month

Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600

AI In Education - Up-level Your Teaching With AI By Cloning Yourself
Forbes 6month

How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.

Trump's Third Term - How AI Can Help To Overthrow The US Government
Forbes 6month

Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.

Sam Altman Says OpenAI Will Release an 'Open Weight' AI Model This Summer
Wired 6month

Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.

Popular Topics